NCT05991180View on ClinicalTrials.gov

Real-World Study on the Efficacy of IBI-322 in Combination With Lenvatinib for the Treatment of Extensive Stage Small Cell Lung Cancer

RecruitingOBSERVATIONAL

Enrollment

160

Participants

Timeline

Start Date

December 25, 2023

Primary Completion Date

December 1, 2024

Study Completion Date

December 31, 2025

Conditions

Extensive-stage Small-cell Lung Cancer

Trial Locations (1)

Unknown

RECRUITING

Hunan Cancer hospital, Changsha

All Listed Sponsors

lead

Hunan Province Tumor Hospital

OTHER